Drug Approval | September 15, 2022
Zydus receives final approval from USFDA for Lenalidomide Capsules
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
TSCS appeals to the Govt. of Telangana to release a G.O for mandatory antenatal test - HbA2 for every pregnant woman to help prevent the birth of Thalassemia Major Children for the well-being of their family & Telangana State
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
The drug will be manufactured at the group's injectables manufacturing facility at Jarod, Gujarat
Routine tests undertaken by women dropped by 35% in 2020
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
Records the largest number of videos of people saying the same sentence uploaded to Facebook in one hour to raise awareness on Iron Deficiency Anaemia
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
